In The Know: Next steps for malignant melanoma treatment

The next round of key opinion leader (KOL) research into the future of malignant melanoma (MM) treatment has begun. Through discussions with 12 of the world’s leading oncologists on the unmet needs in existing treatments and the impact pipeline programmes can bring, this research aims to uncover insights on how the treatment landscape will evolve over the next three to five years. The research will follow the key lines of inquiry set out below.

 

Malignant melanoma key intelligence areas—lines of inquiry

  1. How do KOLs view the recently completed or ongoing clinical trials and how these are going to impact prescribing trends and the future treatment of MM?

  2. How do physicians currently use Merck & Co.’s Keytruda (pembrolizumab) or Bristol-Myers Squibb’s Opdivo (nivolumab)/Yervoy (ipilimumab) combination? What factors influence prescribing behaviour? And what do KOLs think will drive each agent’s uptake?

  3. Can Bristol-Myers Squibb’s Yervoy maintain its position in the MM market and how are the anti-PD1 agents impacting its usage in the treatment strategy?

  4. What are the critical factors for selection of combination therapy [e.g. Mekinist (trametinib) + Tafinlar (dabrafenib) or Cotellic (cobimetinib) + Zelboraf (vemurafenib)] for BRAF mutated  patients? How  treating physicians make their decisions?

  5. How do experts view the arrival of Array’s Braftovi (encorafenib)/Mektovi (binimetinib)? Can it compete with established BRAF/MEK agents?  Which combination agents are preferred by physicians and why?

  6. How do experts view the future of Amgen’s Imlygic (talimogene laherparepvec) and its development in combination with other agents? Which combination agent offer the best prospects with Imlygic? And in which setting do KOLs see a role for Imlygic?

  7. What prospects do vaccine and immunostimulant agents have in the MM space? Where in the treatment strategy is Imlygic used and how do they see it long-term potential?

  8. How do KOLs view the potential of Idera’s tilsotolimod with ipilimumab in advanced melanoma patients that have progressed on immunotherapy? How likely is it that this TLR9 agonist/immunotherapy will play a role in MM treatment?

  9. How do experts view development of Philogen’s darleukin/fibromun (L19-IL2), a recombinant antibody-based angiogenesis inhibitor, in combination with fibromun for the treatment of MM? Can it be a safe and effective treatment?

  10. How do KOLs view the potential of Bristol-Myers Squibb’s relatlimab/nivolumab combination in advanced melanoma? Can it be effective in treating unresectable melanoma or melanoma?

 

Submit any questions you have about this research here.


FirstWord conducts similar research in nearly 30 evolving disease areas. Contact us to learn more.

 

 

To read more Sponsored Story articles, click here.

Reference Articles